Long-term outcomes for patients with lupus nephritis in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the long-term renal and patient survival outcomes of individuals diagnosed with lupus nephritis in China. It includes a cohort of patients who underwent renal biopsy for lupus nephritis, with data collected retrospectively from 1996 to 2016 and prospectively from 2017 onwards. The study will follow these patients to determine if their survival rates improve over time. By analyzing this data, the study seeks to provide insights into the management and prognosis of lupus nephritis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients who had biopsy proven lupus nephritis in The First Affiliated Hospital of Sun Yat-sen University

Exclusion Criteria:

* less than 14 years old
* refused to give written consent

Where it's running

• The First Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Wei Chen, MD PHD — First Affiliated Hospital, Sun Yat-Sen University
• Study coordinator: Xi Xia, MD PHD
• Email: xiax29@mail.sysu.edu.cn
• Phone: +8618825134511

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis

  This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.

  Recruiting Phase 1/2 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Badalona, Barcelona and 7 other locations · NCT07799116

• Lupus Nephritis Care Pathway

  A small group of adults with lupus nephritis will try a team-based care path that uses telemedicine and pharmacist-led support to help manage their treatment and see if it improves adherence and outcomes.

  Recruiting Duke University · Durham, North Carolina · NCT07783152

• Initial glucocorticoid-dose harmonization in childhood lupus nephritis

  This trial tests whether starting children with Lupus Nephritis on a lower or higher prednisone dose makes a difference in treatment outcomes.

  Recruiting at 2 sites Phase 4 Peking Union Medical College Hospital · Beijing, Beijing Municipality and 7 other locations · NCT07719140

• See if empagliflozin helps kidney function in people with lupus nephritis

  This study tests whether adding empagliflozin to standard care improves kidney function in adults with active lupus nephritis.

  Recruiting Phase 4 Beni-Suef University · Banī Suwayf · NCT07700940

• HB2198 for adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus

  This trial will test whether two intravenous doses of HB2198 can safely reduce B cells and improve disease measures in adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus.

  Recruiting Phase 1 Hinge Bio · Brisbane · NCT07491900

• HSK39297 tablets for lupus nephritis

  This trial will test whether once-daily oral HSK39297 (200 mg or 300 mg) is safe and well tolerated compared with placebo in adults with active lupus nephritis.

  Recruiting Phase 2 Haisco Pharmaceutical Group Co., Ltd. · Nanjing, Jiangsu · NCT07363460

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.